Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
PHASE3
This study is a randomized, open-label, multicenter phase III trial designe...
Status
Recruiting
Location
The Fifth Affiliated Hospital,Sun Yat-sen University
A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
PHASE2
This is a prospective, exploratory, non-registration, multi-center clinical...
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
PHASE2
A Randomized, Non-comparative, Multicenter Phase II Clinical Trial of Becot...